194 related articles for article (PubMed ID: 29463369)
61. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
[TBL] [Abstract][Full Text] [Related]
62. Synthesis and in vitro cellular evaluation of novel anti-tumor norcantharidin-conjugated chitosan derivatives.
Xu X; Li Y; Shen Y; Guo S
Int J Biol Macromol; 2013 Nov; 62():418-25. PubMed ID: 24099934
[TBL] [Abstract][Full Text] [Related]
63. Norcantharidin inhibits pre-replicative complexes assembly of HepG2 cells.
Chen S; Qu X; Wan P; Li QW; Wang Z; Guo F; Bai L; Hu Z; Tan W; Li J
Am J Chin Med; 2013; 41(3):665-82. PubMed ID: 23711148
[TBL] [Abstract][Full Text] [Related]
64. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer.
Liu Y; Chen Z; Liu C; Yu D; Lu Z; Zhang N
Biomaterials; 2011 Aug; 32(22):5167-76. PubMed ID: 21521627
[TBL] [Abstract][Full Text] [Related]
65. Intratumoral Injection of Norcantharidin-Loaded Poly(D,L-lactide)-b-Poly(ethylene glycol)-b-Poly(D,L-lactide) Thermosensitive Hydrogel for the Treatment of Primary Hepatocellular Carcinoma.
Xue B; Lei M; Shi K; Wang M; Hao Y; Xiao Y; Yuan L; Peng J; Qian Z
J Biomed Nanotechnol; 2019 Oct; 15(10):2025-2044. PubMed ID: 31462369
[TBL] [Abstract][Full Text] [Related]
66. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
67. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe
Shen JM; Li XX; Fan LL; Zhou X; Han JM; Jia MK; Wu LF; Zhang XX; Chen J
Int J Nanomedicine; 2017; 12():1183-1200. PubMed ID: 28243083
[TBL] [Abstract][Full Text] [Related]
68. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma.
Liu M; Tu J; Feng Y; Zhang J; Wu J
J Nanobiotechnology; 2020 Aug; 18(1):114. PubMed ID: 32811502
[TBL] [Abstract][Full Text] [Related]
69. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer.
Tang P; Sun Q; Yang H; Tang B; Pu H; Li H
Int J Pharm; 2018 Jul; 545(1-2):74-83. PubMed ID: 29715531
[TBL] [Abstract][Full Text] [Related]
70. Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma.
Yang H; Guo W; Xu B; Li M; Cui J
Anticancer Drugs; 2007 Nov; 18(10):1133-7. PubMed ID: 17893513
[TBL] [Abstract][Full Text] [Related]
71. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
72. [Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo].
Fan YZ; Zhao ZM; Fu JY; Chen CQ
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):618-22. PubMed ID: 16784656
[TBL] [Abstract][Full Text] [Related]
73. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
74. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2.
Satomi Y; Nishino H; Shibata S
Anticancer Res; 2005; 25(6B):4043-7. PubMed ID: 16309197
[TBL] [Abstract][Full Text] [Related]
75. iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.
Wang J; Wang H; Li J; Liu Z; Xie H; Wei X; Lu D; Zhuang R; Xu X; Zheng S
ACS Appl Mater Interfaces; 2016 Aug; 8(30):19228-37. PubMed ID: 27381493
[TBL] [Abstract][Full Text] [Related]
76. Supramolecular self-assembled AIE molecules are used in the search for target proteins in norcantharidin.
Ma L; Sun X; Ji W; Zhang B; Li J; Fu W; Zhang X; Qian W; Sheng E; Zhu D
Anal Chim Acta; 2023 Jan; 1239():340642. PubMed ID: 36628744
[TBL] [Abstract][Full Text] [Related]
77. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
Yu CY; Wang YM; Li NM; Liu GS; Yang S; Tang GT; He DX; Tan XW; Wei H
Mol Pharm; 2014 Feb; 11(2):638-44. PubMed ID: 24383625
[TBL] [Abstract][Full Text] [Related]
78. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
Du H; Liu M; Yu A; Ji J; Zhai G
Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
[TBL] [Abstract][Full Text] [Related]
79. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
80. Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells.
Lin CL; Chen CM; Lin CL; Cheng CW; Lee CH; Hsieh YH
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1867-1876. PubMed ID: 28760656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
